Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
McKesson
Colorcon
Moodys

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 212123


Email this page to a colleague

« Back to Dashboard

NDA 212123 describes TAUVID, which is a drug marketed by Avid Radiopharms Inc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the TAUVID profile page.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.
Summary for 212123
Tradename:TAUVID
Applicant:Avid Radiopharms Inc
Ingredient:flortaucipir f-18
Patents:1
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 212123
Generic Entry Date for 212123*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 212123
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123 NDA Eli Lilly and Company 0002-1210 0002-1210-30 1 VIAL, MULTI-DOSE in 1 CAN (0002-1210-30) > 30 mL in 1 VIAL, MULTI-DOSE
TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123 NDA Eli Lilly and Company 0002-1210 0002-1210-50 1 VIAL, MULTI-DOSE in 1 CAN (0002-1210-50) > 50 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength30ML (8.1-51mCi/ML)
Approval Date:May 28, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:May 28, 2025
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Try it FreePatent Expiration:May 19, 2029Product Flag?Substance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength50ML (8.1-51mCi/ML)
Approval Date:May 28, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:May 28, 2025
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Merck
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.